What weekly dose of Boldaxyl 300 do competitive bodybuilders typically use during early contest prep?

Most competitive bodybuilders run 300–500 mg per week during weeks 12–8 before a competition. This range provides measurable lean-mass support and mild erythropoietic stimulation while keeping estrogenic water retention low — a priority once caloric restriction begins. The 300 mg/ml concentration of Boldaxyl 300 makes these doses straightforward: 300 mg equals exactly 1 ml per week.

When should a competitor begin tapering Boldenone Undecylenate dose ahead of show day?

The step-down phase typically begins around week 8 before competition. A common approach reduces the weekly dose by 100 mg every two weeks — for example, from 400 mg to 300 mg to 200 mg — so plasma levels are already declining during the visual conditioning phase. This gradual taper avoids an abrupt hormonal drop while ensuring the compound is not actively spiking during peak week water management.

How does Boldenone Undecylenate compare to testosterone for pre-contest use in terms of water retention?

Boldenone Undecylenate aromatises at roughly half the rate of testosterone under aromatase activity assay conditions, producing less circulating oestradiol at equivalent weekly doses. Lower oestrogen means less subcutaneous water retention — a decisive advantage during a contest prep phase where every gram of extracellular fluid affects stage appearance. This makes it a preferred lean-phase base compound compared to testosterone enanthate or cypionate at matched doses.

How should Boldaxyl 300 be drawn from the 10ml vial for smaller competition-phase doses like 150mg or 200mg?

At 300 mg/ml, a 200 mg dose requires a 0.67 ml draw and a 150 mg dose requires 0.5 ml. Use a fresh 21–23 gauge drawing needle for each extraction to preserve vial sterility. Mark your syringe at the target graduation before drawing, and switch to your injection needle immediately after. These precise sub-millilitre volumes are manageable with a standard 1 ml or 2 ml luer-lock syringe.

How should the Boldaxyl 300 vial be stored after the first puncture?

After first use, store the vial upright at room temperature — between 15–25 °C — away from direct light and heat sources. Refrigeration is not required but acceptable; if refrigerated, allow the oil to reach room temperature before drawing to reduce viscosity. Discard any unused solution that shows cloudiness, particulate matter, or colour change. Under proper storage, a multi-dose vial maintains sterility throughout a standard 10–12 week prep cycle. (2) angle_used

Competition Proven

Kalpa Pharmaceuticals

Boldaxyl 300 300mg/ml 10ml Vial by Kalpa Pharmaceuticals

Name: Boldaxyl 300 300mg/ml 10ml Vial by Kalpa Pharmaceuticals
Brand: Kalpa Pharmaceuticals
SKU: INJ-BOLD-KAL-300-012
Price: 46.00 EUR
Availability: InStock

Boldaxyl 300 is a precision-dosed injectable anabolic agent delivering Boldenone Undecylenate at 300 mg per millilitre in a 10 ml multi-dose vial, formulated specifically to support the structured dose-tapering demands of competitive bodybuilding prep. Each 10 ml vial provides enough volume to manage the graduated weekly reductions that experienced competitors employ as a contest date approaches — without repeated restocking mid-cycle. Quality assurance is embedded at the batch level: HPLC content verification confirms declared concentration, and LAL endotoxin screening clears every lot to injectable-grade sterility standards — both conducted under Kalpa Pharmaceuticals' GMP-aligned production controls.

€46.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers a contest-compatible anabolic foundation with minimal estrogenic water accumulation at standard prep doses
300 mg/ml concentration enables precise weekly volume draws aligned to a structured dose-reduction calendar
10 ml vial volume covers a full 8–10 week tapering phase without mid-cycle resupply
HPLC-UV potency verification on each lot ensures declared concentration matches what enters the syringe
LAL endotoxin testing confirms injectable-grade sterility — critical when injection frequency increases during prep
Erythropoietin-mediated red cell support enhances conditioning-phase training output without additional stimulants
Analytically verified under Kalpa Pharmaceuticals' GMP-aligned production controls for batch-to-batch reliability

Phase	dosage	Note
Early Contest Prep (Weeks 12–9 before show)	400–500 mg/week	Lean-mass maintenance phase; 1.33–1.67 ml per week from Boldaxyl 300 vial; run alongside a calorically controlled diet
Mid Prep / Conditioning (Weeks 8–5 before show)	300–400 mg/week	First step-down increment; reduce by 100 mg every two weeks; monitor haematocrit bi-weekly
Late Prep / Final Taper (Weeks 4–3 before show)	200 mg/week	0.67 ml per injection; plasma levels descending toward competition; subcutaneous fullness from dietary carbohydrates becomes primary focus
Final Injection Window	Last dose 3–4 weeks before competition day	Allows ester clearance during peak-week water and carbohydrate manipulation; no further injections required
PCT Initiation	Begin SERM protocol 4–5 weeks after final injection	Delay accounts for ester clearance; use Clomiphene or Tamoxifen per standard post-cycle protocol

Key takeaways

Plan Boldaxyl 300 dose reductions in 100 mg steps from week 8 before competition.
Schedule the final injection three to four weeks before peak week for plasma management.
Verify each draw volume precisely — 300 mg/ml makes sub-millilitre dose maths exact.
Exploit the lower aromatisation rate versus testosterone to minimise pre-contest water.
Rely on HPLC-confirmed potency for a tapering schedule that tolerates no concentration variance.

Boldenone Undecylenate as a Contest-Prep Dosing Tool

Boldaxyl 300 positions Boldenone Undecylenate as a competition-phase compound whose dosing architecture — not merely its pharmacology — defines its practical role in pre-contest programming. Experienced competitors treat dosing structure during the final eight to twelve weeks before a show as a discipline in itself: the question is not simply how much to run, but how and when to reduce. Boldenone Undecylenate's gradual plasma clearance, governed by ester hydrolysis over multiple weeks, makes it a compound where weekly dose decisions carry consequences that extend well past the injection date.

Standard Contest-Phase Dose Ranges and Their Rationale

Contest-prep dosing for Boldenone Undecylenate typically spans 300–500 mg per week during the early conditioning phase — roughly weeks 12 through 8 before competition — providing a lean-mass scaffold without the estrogenic water load associated with higher-aromatising androgens. Compared to testosterone at equivalent weekly doses, Boldenone Undecylenate aromatises at approximately half the rate (measured via aromatase activity assays), making it a preferred base compound when subcutaneous water retention must be minimised ahead of peak week. From week 8 onward, many competitive athletes begin a structured step-down: reducing by 100 mg increments on a two-week cadence, so that plasma levels are already declining during the final polish phase rather than dropping sharply in the days before judging. Kalpa Pharmaceuticals' 300 mg/ml concentration supports this graduated protocol — a 300 mg weekly dose requires exactly 1 ml, and step-downs to 200 mg or 150 mg involve straightforward 0.67 ml and 0.5 ml draws respectively.

Timing, Tapering, and Competition-Day Clearance

The long-acting ester means the final injection timing relative to competition day requires deliberate calculation. Most prep coaches schedule the last Boldaxyl 300 injection no later than three to four weeks before peak week, allowing plasma concentrations to descend during the visual refinement period when dietary water and carbohydrate manipulation dominate. Kalpa Pharmaceuticals manufactures Boldaxyl 300 under a quality framework that includes HPLC-UV potency verification and LAL endotoxin testing on every production lot — meaning the declared 300 mg/ml concentration is analytically confirmed, not assumed. Predictable potency is not a marketing claim here; it is a prerequisite for reliable dose calculation in a context where even modest concentration variance would misalign the tapering schedule a competitor has built over months.

Usage

Calculate your contest date and work backward 12 weeks to establish cycle start; map each weekly dose and the two-week step-down intervals on a calendar before your first injection.
Draw from the Boldaxyl 300 vial using a fresh 21-gauge needle each time; at 300 mg/ml, confirm your target volume against the syringe graduation before switching to your injection needle.
Inject intramuscularly into the glute, quad, or delt on a consistent weekly schedule — split into two equal administrations (e.g. Monday and Thursday) to maintain steadier plasma levels during the conditioning phase.
At week 8 before your show, begin the step-down: reduce by 100 mg per week on a fortnightly cadence; record each injection date and dose in a training log to stay aligned with your tapering plan.
Schedule blood work — including haematocrit, haemoglobin, and serum oestradiol — at the start of each new dose tier; use these results to confirm the taper is proceeding as planned and to detect any haematocrit elevation requiring medical attention.
Administer your final injection three to four weeks before competition day; during the remaining weeks, shift focus entirely to dietary carbohydrate and water manipulation as plasma Boldenone levels descend naturally.

Warnings

Contraindications: Boldaxyl 300 is contraindicated in individuals with androgen-sensitive prostate or breast conditions, elevated baseline haematocrit (above 50%), active cardiovascular disease, hepatic impairment, or allergy to sesame or benzyl alcohol carrier components. Female athletes face significant virilisation risk at any dose used in a contest context.

Side Effects: Erythropoietin-driven haematocrit elevation is the primary concern during extended prep cycles — rises above 52% increase thrombotic risk and require immediate dose review. Androgenic effects including accelerated scalp hair loss and acne may occur. Suppression of the hypothalamic-pituitary-gonadal axis is expected; endogenous testosterone production does not recover without a structured post-cycle intervention.

Monitoring: Obtain a full blood count, lipid panel, and sex hormone panel at cycle start and at each two-week dose-reduction point. Haematocrit should be the primary tracked marker during the tapering phase. If haematocrit exceeds 52%, suspend injections and consult a physician before proceeding. Blood pressure should be self-monitored weekly throughout the prep cycle.

PCT: Initiate post-cycle therapy with a selective oestrogen receptor modulator — Clomiphene Citrate at 50 mg/day or Tamoxifen at 20 mg/day for four weeks — approximately four to five weeks after the final Boldaxyl 300 injection, timed to allow ester clearance before SERM therapy begins.

Frequently asked questions

What weekly dose of Boldaxyl 300 do competitive bodybuilders typically use during early contest prep?: Most competitive bodybuilders run 300–500 mg per week during weeks 12–8 before a competition. This range provides measurable lean-mass support and mild erythropoietic stimulation while keeping estrogenic water retention low — a priority once caloric restriction begins. The 300 mg/ml concentration of Boldaxyl 300 makes these doses straightforward: 300 mg equals exactly 1 ml per week.
When should a competitor begin tapering Boldenone Undecylenate dose ahead of show day?: The step-down phase typically begins around week 8 before competition. A common approach reduces the weekly dose by 100 mg every two weeks — for example, from 400 mg to 300 mg to 200 mg — so plasma levels are already declining during the visual conditioning phase. This gradual taper avoids an abrupt hormonal drop while ensuring the compound is not actively spiking during peak week water management.
How does Boldenone Undecylenate compare to testosterone for pre-contest use in terms of water retention?: Boldenone Undecylenate aromatises at roughly half the rate of testosterone under aromatase activity assay conditions, producing less circulating oestradiol at equivalent weekly doses. Lower oestrogen means less subcutaneous water retention — a decisive advantage during a contest prep phase where every gram of extracellular fluid affects stage appearance. This makes it a preferred lean-phase base compound compared to testosterone enanthate or cypionate at matched doses.
How should Boldaxyl 300 be drawn from the 10ml vial for smaller competition-phase doses like 150mg or 200mg?: At 300 mg/ml, a 200 mg dose requires a 0.67 ml draw and a 150 mg dose requires 0.5 ml. Use a fresh 21–23 gauge drawing needle for each extraction to preserve vial sterility. Mark your syringe at the target graduation before drawing, and switch to your injection needle immediately after. These precise sub-millilitre volumes are manageable with a standard 1 ml or 2 ml luer-lock syringe.
How should the Boldaxyl 300 vial be stored after the first puncture?: After first use, store the vial upright at room temperature — between 15–25 °C — away from direct light and heat sources. Refrigeration is not required but acceptable; if refrigerated, allow the oil to reach room temperature before drawing to reduce viscosity. Discard any unused solution that shows cloudiness, particulate matter, or colour change. Under proper storage, a multi-dose vial maintains sterility throughout a standard 10–12 week prep cycle. (2) angle_used

Manufacturer

Kalpa Pharmaceuticals' origin story is rooted in a deliberate decision to serve the international bodybuilding market through pharmaceutical-grade manufacturing standards rather than the looser controls historically associated with underground production. Founded with an explicit focus on injectable and oral anabolics for performance-oriented end users, the brand built its early reputation not through marketing volume but through documentation: independently audited batch records, HPLC-UV chromatograms made accessible to distributors, and LAL endotoxin certificates issued per production lot rather than per product line. This documentation-forward approach distinguished Kalpa during a period when the broader UGL market operated largely on trust. The brand's catalogue architecture — spanning testosterone esters, nandrolone compounds, boldenone preparations, and ancillaries — reflects a systematic rather than opportunistic product strategy, with concentration variants selected to serve specific dosing contexts rather than simply to differentiate SKUs.

Product details

Brand	Kalpa Pharmaceuticals
Active ingredient	boldenone undecylenate
Also known as	Equipoise, EQ, Boldenone Undecylenate, Boldaxyl 300, Kalpa Pharmaceuticals Equipoise
Strength	300 mg
Form	Vial
Pack size	1 piece
Item number	INJ-BOLD-KAL-300-012

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00

Stack it with

Pairs well with these products.

High Concentration